WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Anticoagulant_Master_CMAP_v3, Secondary efficacy endpoint hasOutcomeAssessment Net clinical benefit (NCB), Secondary efficacy endpoint hasOutcomeAssessment Composite endpoint, CRF: Non-CNS systemic embolism (SEE) asObservationTime Date/Time of start of randomization period, Secondary efficacy endpoint hasOutcomeAssessment Individual endpoint, CRF: Stroke asObservationTime Date/Time of start of randomization period, Primary efficacy endpoints hasOutcomeAssessment Time to the first occurrence of Non-CNS systemic embolism (SEE), Primary efficacy endpoints hasOutcomeAssessment Time to the first occurrence of stroke, CRF: Non-CNS systemic embolism (SEE) asObservationTime Date/Time of end of trial, Repeated concepts/instances (e.g. Stroke, Death) are denoted by dotted outline, Liver function test (LFT) hasMeasurementTime Defined timepoints, Secondary efficacy endpoints are denoted by italics font, Clinical endpoint hasObservation Safety endpoint, Net clinical benefit (NCB) hasObservation Individual secondary endpoints, Therapeutic Efficacy Point is the intersection of Observation or Assessment, Clinical endpoint hasObservation Secondary efficacy endpoint, Time to the first occurrence of Non-CNS systemic embolism (SEE) hasObservation CRF: Non-CNS systemic embolism (SEE), Main concept groups (e.g. Safety endpoints) are denoted by Larger bold font with thicker outline, Therapeutic Efficacy Point is the intersection of Physiolgoical Process, Individual endpoint hasObservation Individual secondary endpoints, Concepts which may be removed (for simplicity) are denoted by Gray shading